By proceeding, you agree to our Terms of Use and Privacy Policy.
Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities.
09-11 March 2022
The Festival of Biologics brings together pharma & biotech, academics and research institutes, together with their partners across the value chain.
Event Ended
USA
Paid
San Diego
12-14 July 2022
From Leveraging Emerging Predictive Technologies to Engineering a Human-Physiologically Relevant Models – Deepen Our Understanding of Tumor Biology, Resistance Mechanisms & Dosing Strategy Following the success of KRAS, HER2, BCMA, drug developers ha
Boston
02-04 November 2022
Biologic drug discovery, development, manufacturing, pricing & market access, Clinical Trials. The Festival of Biologics brings together pharma & biotech, academics and research institutes, together with their partners across the value chain.
Switzerland
Basel
04-08 December 2022
THE #1 ANTIBODY ENGINEERING CONFERENCE FOR ACCELERATING NEXT GENERATION ANTIBODIES TO COMMERCIAL SUCCESS Brand New Session Themes for 2022: How to Develop an Antibody-based Drug from Discovery to IND? Adaptive Immune Receptor Repertoire Data Processi
Hybrid
24-26 January 2023
With 2023 on track to see further growth in the immuno-oncology field, the availability of tools that offers drug developers & researchers advantages that weren’t available to them even a few years ago is increasing rapidly.
San Francisco
20-22 March 2023
22-23 June 2023
Our 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference to be held on 22nd - 23rd June 2023, in Boston, would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientist
07-08 August 2023
Great progress has been made in studying cancer immunology and the development of immunotherapies. The complexity of the immune system and the duplicity of cancer, plus the expense of treatments and variable patient responses, make for a perfect data
Cell therapies such as CAR Ts are now a proven treatment approach for hematological cancers, but challenges remain around CAR T’s ability to target solid tumors. Cambridge Healthtech Institute’s Tenth Annual Advances in CAR T Therapy conference bring
Bispecific antibodies are generating increased excitement for their potential to effectively target complex diseases through a dual-engagement approach. There are many new and powerful breakthroughs with bispecific antibodies relating to fine tuning
07-09 August 2023
Over the past 11 years, CHI’s Immuno-Oncology Summit has become the leading annual meeting focusing on the next wave of biotherapeutics, advances in technologies, and the valuable exchange of high-quality research from all disciplines of immuno-oncol
08-09 August 2023
Advances in harnessing the immune system for therapeutic development have resulted in a robust pipeline of immuno-oncology therapies and novel combinations. A successful program requires appropriate models and tools for preclinical evaluation and eff
Up until now, the cell therapy industry has been driven by the remarkable success of CAR T therapy. However, many believe the future of immunotherapy lies with other cell types such as NKs, Gamma Deltas, B Cells, TILs, and B cells, which offer many a
In recent years, Immunotherapy has been at the forefront of oncology research. However, this has not been without issues. Some of which include applications to solid tumors, regulating biodistribution, and serious side effects. During this conference
13-15 November 2023
Vaccines Summit 2023 is an esteemed international conference organized by Scientia Meetings, bringing together participants from around the world. This highly anticipated event is scheduled to take place from November 13th to 15th, 2023, under the co
13-16 December 2023
The latest science and research on antibody engineering, design and selection diving into critical topics including Neurodegenerative Diseases, Tumor Microenvironment in Antibody Therapy, Antibody Immune Agonist, Bi-Specifics, ADCs, Protein-Based Deg